Annual Report 2025 8 impact it has on their lives. Our aim is to mitigate that impact by leveraging a technology that is targeted at the very place where inflammation begins at the cellular level. These diseases also represent very large markets. Worth US$163.2 billion in 2024, the global autoimmune disease therapeutics market alone is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market, which is relevant to our exploration of Sofra in the cancer space, was US$43 billion in 2023 and is projected to hit US$284 billion by 2033. When it comes to further development of our platform, as a small company we cannot of course do everything ourselves, but nor would we want to, for example, take every asset to an expensive latestage clinical trial. That is why we continue to look for partners who would work with us scientifically and commercially to take some of these assets forward. Over the past year we have seen external interest in our technology continue to rise, and we know that our assets are of interest to different companies because of the positive data we have produced and the expensive experiments these companies are conducting on our assets at their own cost. It is therefore good to report that we are progressing these relationships, finding new ones, and looking to build shareholder value with every step. With these opportunities in mind, we are also implementing a robust intellectual property strategy to protect our work from the ground up. Our assets are based on a significant breakthrough discovery that has advanced our understanding of the human immune system, which was made by Associate Professor Michael Gantier and his team at Hudson Institute of Medical Research. Both he and his work are attracting more interest than ever. We are also seeing this trend reflected in the frequency with which we now showcase our work. Shareholders will be pleased to know that we are being invited to speak more often at conferences, and increasingly in more prominent places on the agenda. These presentations are often highly technical, but the rise in interest suggests we are attracting attention in important international markets, which in turn opens doors to more opportunities down the track. Our current progress on the research front, combined with our clinical trial, gives us much confidence for the future. We are therefore deeply grateful to those shareholders and investors who recently extended their convertible notes to support our ongoing funding requirements. Your support has strengthened us for the future by making a commitment when it matters most. We can now focus on achieving the next goals on our list, which include the next stage of the SOF-SKN trial, further developing the SOF-VAC™ portfolio, expanding our pipeline, securing publication of the team’s foundational research, and moving towards commercial outcomes. We are all working hard on these various initiatives, and I can confidently say that all of my colleagues are genuinely excited about the future and the possibilities we can create together. I would like to personally thank all of our shareholders for your support, and your interests remain our highest priority as we continue to meet our targets and build a successful company. Yours sincerely, Dr Gisela Mautner CEO
RkJQdWJsaXNoZXIy MjE2NDg3